Beese Fulmer Investment Management Inc. Sells 3,247 Shares of Pfizer Inc. (NYSE:PFE)

Beese Fulmer Investment Management Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,819 shares of the biopharmaceutical company’s stock after selling 3,247 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Pfizer were worth $1,375,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of PFE. Keystone Financial Group Inc. acquired a new stake in Pfizer during the 4th quarter worth about $114,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Pfizer by 7.5% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 756,400 shares of the biopharmaceutical company’s stock worth $20,067,000 after purchasing an additional 52,578 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Pfizer by 7.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 14,075,637 shares of the biopharmaceutical company’s stock valued at $373,427,000 after buying an additional 956,873 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Pfizer by 19,570.5% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 800,000 shares of the biopharmaceutical company’s stock worth $21,224,000 after buying an additional 795,933 shares in the last quarter. Finally, Strategic Financial Concepts LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $2,281,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 2.3 %

NYSE PFE opened at $25.83 on Friday. The stock’s 50-day simple moving average is $26.29 and its two-hundred day simple moving average is $27.78. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $146.35 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 0.66 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. Research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.66%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.